Chinese clinical-stage biotech developing small-molecule targeted cancer therapies, including KRAS-pathway inhibitors.
Chinese clinical-stage biotech developing small-molecule targeted cancer therapies, including KRAS-pathway inhibitors.
In one line: A Chinese Mirati Therapeutics-style KRAS/oncology biotech.
Moat: narrow (IP / patents). Patent-protected small-molecule oncology candidates targeting hard-to-drug pathways.
Headquarters: Shanghai, China · Founded: 2017 · Employees: 102
Size Genfleet Therapeutics (Shanghai) (2595.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $912M, the 601st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.72 on 18 Nov 2026.
Performance Over six months the shares fell 42.4%, against -16.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 55.1% over the last twelve months (peer median +6.8%); the operating margin is -456.9% (peer median 8.0%).
Valuation It trades at 55.9× enterprise value to sales against a peer median of 3.2× (most expensive of 19).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$93.9M | HK$141M | HK$114M | HK$81.5M | HK$122M |
| Revenue growth | — | +24% | +39% | -33% | — |
| Gross profit | HK$28.7M | HK$80.1M | HK$76.2M | HK$60.8M | HK$88.2M |
| EBITDA | -HK$419M | -HK$268M | -HK$296M | -HK$300M | -HK$284M |
| Net income | -HK$1.45B | -HK$1.95B | -HK$735M | -HK$562M | -HK$320M |
| Free cash flow | -HK$425M | -HK$150M | -HK$225M | -HK$224M | -HK$348M |
| Capital expenditure | HK$6.32M | HK$121,467 | HK$290,572 | HK$656,369 | HK$13.8M |
| Total debt | n/a | HK$113M | HK$73.8M | HK$34.9M | HK$61.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) 2595.HK | $912M | -42% | -55% | -457% | 55.9× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| InnoCare Pharma 9969.HK | $2.01B | -10% | +146% | 35% | 2.8× | -2.0% |
| Ascentage Pharma Group International 6855.HK | $1.18B | -34% | +70% | -220% | 13.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2595.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -33.6% | -8.3% | lowest of 21 |
| 6-month return | -42.4% | -16.9% | 3rd lowest of 20 |
| Distance from 52-week high | -62.7% | -44.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | -55.1% | +6.8% | lowest of 19 |
| Operating margin | -456.9% | 8.0% | 3rd lowest of 19 |
| EV / Sales | 55.9× | 3.2× | most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |